


Ask a doctor about a prescription for LUMIGAN 0.1 mg/ml EYE DROPS SOLUTION
Package Leaflet: Information for the User
LUMIGAN 0.1mg/ml, eye drops, solution
bimatoprost
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the package leaflet:
LUMIGAN is a medicine for glaucoma. LUMIGAN belongs to a group of medicines called prostamides.
LUMIGAN eye drops are used to reduce high pressure in the eye. LUMIGAN can be used alone or with other eye drops called beta blockers that also reduce pressure.
The eye contains a clear, watery liquid that keeps the inside of the eye healthy. This liquid is constantly drained out of the eye and new liquid is produced to replace it. If the liquid is not drained quickly enough, the pressure inside the eye increases. LUMIGAN works by increasing the drainage of the liquid. This reduces the pressure inside the eye. If this pressure is not reduced, it could lead to a disease called glaucoma and damage your vision.
Do not use LUMIGAN 0.1 mg/ml:
Warnings and precautions:
Consult your doctor or pharmacist before starting to use LUMIGAN 0.1 mg/ml.
During treatment, LUMIGAN may cause loss of fat around the eye, which can cause deepening of the eyelid fold, sunken eyes (enophthalmos), drooping of the upper eyelid (ptosis), stretching of the skin around the eye (involution of the dermatocalasis), and the white part of the eye becomes more visible (inferior scleral show). The changes are usually mild, but if they worsen, they can affect your field of vision. The changes may disappear if you stop using LUMIGAN. LUMIGAN may also cause darkening and growth of eyelashes, as well as darkening of the skin around the eyelid. The color of the iris may darken. These changes may be permanent and more noticeable if only one eye is being treated.
Children and adolescents
LUMIGAN has not been studied in patients under 18 years of age and should not be used in patients under 18 years of age.
Other medicines and LUMIGAN:
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.
LUMIGAN may pass into breast milk, so you should not use it if you are breastfeeding.
Driving and using machines:
After instilling LUMIGAN, you may experience blurred vision for a short time. Do not drive or use machines until your vision is clear.
LUMIGAN 0.1 mg/ml contains benzalkonium chloride
This medicine contains 0.6 mg of benzalkonium chloride in every 3 ml of solution, which is equivalent to 0.2 mg/ml.
Do not use the eye drops when wearing contact lenses. The benzalkonium chloride in Lumigan can be absorbed by soft contact lenses and may change the color of the contact lenses. Remove contact lenses before using this medicine and wait 15 minutes before putting them back. Benzalkonium chloride may cause eye irritation, especially if you have dry eye or other corneal diseases (the transparent layer on the front of the eye). Consult your doctor if you feel any unusual sensation, itching, or pain in the eye after using this medicine.
Follow the instructions for administration of the medicine given by your doctor or pharmacist. In case of doubt, ask your doctor or pharmacist.
LUMIGAN should only be used in the eye. The recommended dose is one drop of LUMIGAN in each eye that needs treatment, once a day, in the evening.
If you use LUMIGAN with another eye medicine, wait at least 5 minutes between using LUMIGAN and the other eye medicine.
Do not use the medicine more than once a day, as this may reduce the effectiveness of the treatment.
Instructions for use:
Do not use the container if the protective seal is broken before using it for the first time.

Wipe away any excess that runs down your cheek.
If the drop misses your eye, try again.
To help prevent infections and eye injuries, avoid touching the tip of the container to the eye or any other surface. Replace the cap and close the container immediately after use.
If you use more LUMIGAN 0.1 mg/ml than you should
If you use more LUMIGAN than you should, it is unlikely to cause you any serious harm. Apply the next dose at the usual time. If you are concerned, talk to your doctor or pharmacist.
If you forget to use LUMIGAN 0.1 mg/ml
If you forget to apply LUMIGAN, use one drop as soon as you remember, and then go back to your usual routine. Do not apply a double dose to make up for the forgotten dose.
If you stop using LUMIGAN 0.1 mg/ml
LUMIGAN should be used every day to work properly. If you stop using LUMIGAN, the pressure in the eye may increase, so consult your doctor before stopping treatment.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
These may affect 1 or more patients in every 10
These may affect 1 to 9 patients in every 100
Affecting the eye
Affecting the skin
Uncommon side effects
These may affect 1 to 9 patients in every 1,000
Affecting the eye
Affecting the skin
Affecting the body
Rare side effects
These may affect 1 to 9 patients in every 10,000
Affecting the eye
Affecting the body
In addition to the side effects of LUMIGAN 0.1 mg/ml, the following side effects have been observed with another medicine that contains a higher concentration of bimatoprost (0.3 mg/ml):
Other side effects reported with eye drops that contain phosphate
In very rare cases, some patients with severe damage to the transparent layer on the front of the eye (the cornea) have developed cloudy spots on the cornea due to calcium deposits during treatment.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of the month shown.
You should throw away the container at the latest 4 weeks after you first opened it, even if there are still some drops left. This will help prevent infections. To remind you, write down the date you opened the container on the space provided on the carton.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of LUMIGAN 0.1 mg/ml
Appearance of LUMIGAN 0.1 mg/ml and contents of the container
LUMIGAN is a clear, colorless eye drop solution in a container that contains 1 or 3 plastic bottles, each with a screw cap. The bottle is only filled up to about half, and each bottle contains 3 ml of solution. The contents are sufficient for 4 weeks of treatment. Only some pack sizes may be marketed.
Marketing authorisation holder and manufacturer:
AbbVie Deutschland GmbH & Co. KG
Knollstraße
67061 Ludwigshafen
Germany
You can get more information about this medicine by contacting the local representative of the marketing authorisation holder.
Belgium/Belgique/Belgien Luxembourg/Luxemburg/Nederland Allergan n.v. Tel: +32 (0)2 351 24 24 | Iceland Actavis Pharmaceuticals Iceland ehf. Phone: +354 550 3300 |
Bulgaria Allergan Bulgaria EOOD Phone: +359 (0) 800 20 280 | Italy Allergan S.p.A Phone: +39 06 509 562 90 |
Czech Republic Allergan CZ s.r.o. Phone: +420 800 188 818 | Latvia Allergan Baltics UAB Phone: +371 676 60 831 |
Denmark/Norway/Finland/Sweden Allergan Norden AB Phone: +45 80 88 45 60 (DK) +47 80 01 04 97 (NO) +358 800 115 003 (FI) +46 (0)8 594 100 00 (SE) | Lithuania Allergan Baltics UAB Phone: +37 052 072 777 |
Germany Pharm-Allergan GmbH Phone: +49 69 92038 1050 | Hungary Allergan Hungary Kft. Phone: +36 80 100 101 |
Estonia Allergan Baltics UAB Phone: + 37 2 634 6109 | Austria Pharm-Allergan GmbH Phone: +43 1 99460 6355 |
Greece/Cyprus Allergan Hellas Pharmaceuticals S.A. Phone: +30 210 74 73 300 | Poland Allergan Sp. z o.o. Phone: +48 22 256 37 00 |
Spain Allergan S.A. Phone: +34 91 807 6130 | Portugal Profarin Lda. Phone: +351 21 425 3242 |
France Allergan France SAS Phone: +33 (0)1 49 07 83 00 | Romania Allergan S.R.L. Phone: +40 21 301 53 02 |
Croatia Ewopharma d.o.o. Phone: +385 1 6646 563 | Slovenia Ewopharma d.o.o. Phone: +386 (0) 590 848 40 |
Ireland/Malta Allergan Pharmaceuticals Ireland Phone: +353 1800 931 787 (IE) +356 27780331 (MT) | Slovakia Allergan SK s.r.o. Phone: +421 800 221 223 United Kingdom Allergan Ltd Phone: +44 (0) 1628 494026 |
Date of last revision of this leaflet:
Detailed information on this medicine is available on the European Medicines Agency website http://www.ema.europa.eu//
The average price of LUMIGAN 0.1 mg/ml EYE DROPS SOLUTION in November, 2025 is around 7.34 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for LUMIGAN 0.1 mg/ml EYE DROPS SOLUTION – subject to medical assessment and local rules.